RT Journal Article
SR Electronic
T1 Evolution of COVID-19 symptoms during the first 9 months after illness onset
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.05.21256710
DO 10.1101/2021.05.05.21256710
A1 Elke Wynberg
A1 Hugo van Willigen
A1 Maartje Dijkstra
A1 Anders Boyd
A1 Neeltje A. Kootstra
A1 Joost G. van den Aardweg
A1 Marit J. van Gils
A1 Amy Matser
A1 Marije R. de Wit
A1 Tjalling Leenstra
A1 Godelieve de Bree
A1 Menno D. de Jong
A1 Maria Prins
A1 the RECoVERED Study Group
YR 2021
UL http://medrxiv.org/content/early/2021/05/11/2021.05.05.21256710.abstract
AB Background Few longitudinal data on COVID-19 symptoms across the full spectrum of disease severity are available. We evaluated symptom onset, severity and recovery up to nine months after illness onset.Methods The RECoVERED Study is a prospective cohort study based in Amsterdam, the Netherlands. Participants aged>18 years were recruited following SARS-CoV-2 diagnosis via the local Public Health Service and from hospitals. Standardised symptom questionnaires were completed at recruitment, at one week and month after recruitment, and monthly thereafter. Clinical severity was defined according to WHO criteria. Kaplan-Meier methods were used to compare time from illness onset to symptom recovery, by clinical severity. We examined determinants of time to recovery using multivariable Cox proportional hazards models.Results Between 11 May 2020 and 31 January 2021, 301 COVID-19 patients (167[55%] male) were recruited, of whom 99/301(32.9%) had mild, 140/301(46.5%) moderate, 30/301(10.0%) severe and 32/301(10.6%) critical disease. The proportion of symptomatic participants who reported at least one persistent symptom at 12 weeks after illness onset was greater in those with severe/critical disease (81.7%[95%CI=68.7-89.7%]) compared to those with mild or moderate disease (33.0%[95%CI=23.0-43.3%] and 63.8%[95%CI=54.8-71.5%]). Even at nine months after illness onset, almost half of all participants (42.1%[95%CI=35.6-48.5]) overall continued to report ≥1 symptom. Recovery was slower in participants with BMI≥30kg/m2 (HR 0.51[95%CI=0.30-0.87]) compared to those with BMI<25kg/m2, after adjusting for age, sex and number of comorbidities.Conclusions COVID-19 symptoms persisted for nine months after illness onset, even in those with mild disease. Obesity was the most important determinant of speed of recovery from symptoms.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe RECoVERED study received funding from ZonMw (project number 10150062010002) and a Research & Development grant (21-14) from the Public Health Service of AmsterdamAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Medical Ethics Examination Committee (METC) of the Amsterdam Medical CentersAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesInformation can be obtained from the corresponding author, Elke Wynberg (ewynberg@ggd.amsterdam.nl)